$CLOV earnings report

Clover Health reported third quarter 2026 GAAP net income of $6 million, total revenues of $759 million, and raised full-year 2026 guidance across all disclosed metrics. AlphAI read Clover Health Investments's Third quarter 2026 filing as strong. 2 quarters are on record below.

Third quarter 2026

AlphAI · Earnings readCLOV · Third quarter 2026 · ended September 30, 2026

Clover Health reported third quarter 2026 GAAP net income of $6 million, total revenues of $759 million, and raised full-year 2026 guidance across all disclosed metrics.

✓Strong quarter

Third-quarter revenue increased 52.9%, GAAP net income improved to $6.4 million from a $24.4 million loss, consolidated gross profit increased 77.3%, and the company raised the low end of full-year guidance for revenue, GAAP net income, consolidated gross profit, Adjusted EBITDA, and average Medicare Advantage membership.

Revenue
$759M
52.9% y/y
Insurance Segment, three months ended September 30, 2026
$749M
56.3% y/y
EPS · GAAP
$0.01
Full Year 2026 outlook
$2.97 billion - $3.00 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues, three months ended September 30, 2026GAAP$759.3M–52.9%
Premiums earned, net, three months ended September 30, 2026GAAP$748.8M––
Other income, three months ended September 30, 2026GAAP$10.52M––
Net medical claims incurred, three months ended September 30, 2026GAAP$629.5M––
Consolidated Gross profit, three months ended September 30, 2026non-GAAP$129.8M–77.3%
Salaries and benefits, three months ended September 30, 2026GAAP$55.97M––
General and administrative expenses, three months ended September 30, 2026GAAP$66.83M––
SG&A, three months ended September 30, 2026GAAP$122.8M–26.5%
Adjusted SG&A, three months ended September 30, 2026non-GAAP$113.8M–60.1%
Adjusted SG&A as a percentage of Total revenues, three months ended September 30, 2026non-GAAP15.0%–70 bps
Depreciation and amortization, three months ended September 30, 2026GAAP$610K––
Total operating expenses, three months ended September 30, 2026GAAP$752.9M––
Income (loss) from operations, three months ended September 30, 2026GAAP$6.43M––
Net income (loss), three months ended September 30, 2026GAAP$6.4M–N/A*
Basic earnings (loss) per share, three months ended September 30, 2026GAAP$0.01––
Diluted earnings (loss) per share, three months ended September 30, 2026GAAP$0.01––
Comprehensive income (loss), three months ended September 30, 2026GAAP$4.63M––
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$16.1M–666.7%
Adjusted Net income, three months ended September 30, 2026non-GAAP$15.4M–805.9%
Insurance Benefits Expense Ratio, three months ended September 30, 2026non-GAAP91.1%–(240 bps)
Average Medicare Advantage membership, three months ended September 30, 2026other158,383–46.3%
Total revenues, nine months ended September 30, 2026GAAP$2.25B–56.7%
Consolidated Gross profit, nine months ended September 30, 2026non-GAAP$442.4M–57.0%
SG&A, nine months ended September 30, 2026GAAP$378.9M–19.7%
Adjusted SG&A, nine months ended September 30, 2026non-GAAP$345.2M–45.8%
Adjusted SG&A as a percentage of Total revenues, nine months ended September 30, 2026non-GAAP15.3%–(120 bps)
Net income (loss), nine months ended September 30, 2026GAAP$61.8M–N/A*
Basic earnings (loss) per share, nine months ended September 30, 2026GAAP$0.12––
Diluted earnings (loss) per share, nine months ended September 30, 2026GAAP$0.11––
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$97.2M–116.0%
Adjusted Net income, nine months ended September 30, 2026non-GAAP$95.5M–118.5%
Insurance Benefits Expense Ratio, nine months ended September 30, 2026non-GAAP88.4%–(100 bps)
Average Medicare Advantage membership, nine months ended September 30, 2026other156,610–48.8%

Segments

SegmentRevenueq/qy/y
Insurance Segment, three months ended September 30, 2026Average Medicare Advantage membership was 158,383, up 46.3% year-over-year; Insurance BER was 91.1%, compared with 93.5%.$748.8M–56.3%
Insurance Segment, nine months ended September 30, 2026Average Medicare Advantage membership was 156,610, up 48.8% year-over-year; Insurance BER was 88.4%, compared with 89.4%.$2.23B–58.7%

Full Year 2026 outlook

  • Revenue$2.97 billion - $3.00 billion
  • NoteGAAP Net income: $25 million - $35 million
  • NoteConsolidated Gross profit: $540 million - $555 million
  • NoteAdjusted EBITDA: $75 million - $85 million
  • NoteAverage Medicare Advantage membership: 157,000 - 158,000

Capital returns

  • Repurchases of common stock: — for the nine months ended September 30, 2026.
  • Cash paid for shares withheld related to stock-based compensation: $(9,680) thousand for the nine months ended September 30, 2026.

What drove it

  • Third-quarter average Medicare Advantage membership was 158,383, up 46.3% year-over-year.
  • Insurance revenue was $748.8 million, up 56.3% year-over-year in the third quarter.
  • Insurance BER improved by (240 bps) year-over-year to 91.1% in the third quarter.
  • The flagship PPO represented ~98% of current membership and received a 5 Star rating for Payment Year 2028.
  • Management cited maturing member cohorts, continued operating leverage, and strong Star ratings performance in its outlook for 2027.

Concerns

  • Other income was $10,520 thousand in the third quarter, compared with $17,522 thousand in the prior-year period.
  • Adjusted SG&A as a percentage of Total revenues was 15.0% in the third quarter, compared with 14.3% in the prior-year period.
  • Unpaid claims were $269,101 thousand at September 30, 2026, compared with $153,250 thousand at December 31, 2025.
  • Third-quarter Insurance BER of 91.1% was higher than the 88.4% reported for the nine months ended September 30, 2026.

What to watch

  • Full-year 2026 total revenues guidance of $2.97 billion - $3.00 billion.
  • Full-year 2026 GAAP Net income guidance of $25 million - $35 million.
  • Full-year 2026 Consolidated Gross profit guidance of $540 million - $555 million.
  • Full-year 2026 Adjusted EBITDA guidance of $75 million - $85 million.
  • Average Medicare Advantage membership guidance of 157,000 - 158,000.
  • 2027 AEP tracking and the effect of the 5 Star rating for Payment Year 2028.

Balance sheet and cash flow

  • Total cash, cash equivalents, and investments: $512.6 million at September 30, 2026, compared with $395.9 million at September 30, 2025.
  • Cash and cash equivalents: $268,067 thousand at September 30, 2026, compared with $78,301 thousand at December 31, 2025.
  • Total assets: $753,680 thousand at September 30, 2026, compared with $541,011 thousand at December 31, 2025.
  • Total liabilities: $362,808 thousand at September 30, 2026, compared with $232,307 thousand at December 31, 2025.
  • Net cash provided by operating activities: $203,462 thousand for the nine months ended September 30, 2026, compared with $1,218 thousand.
  • Purchases of property and equipment: $(2,434) thousand for the nine months ended September 30, 2026, compared with $(1,446) thousand.
  • Net cash used in investing activities: $(7,976) thousand for the nine months ended September 30, 2026, compared with $39,071 thousand provided by investing activities.
  • Net cash used in financing activities: $(5,720) thousand for the nine months ended September 30, 2026, compared with $(44,777) thousand.
  • Net increase in cash and cash equivalents: $189,766 thousand for the nine months ended September 30, 2026, compared with a net decrease of $(4,488) thousand.

Analysis

Clover Health delivered strong third-quarter growth and a return to GAAP profitability. Total revenues increased 52.9% to $759.3 million, while average Medicare Advantage membership increased 46.3% to 158,383. Insurance revenue increased 56.3% to $748.8 million. Third-quarter GAAP net income was $6.4 million, compared with a loss of $(24.4) million in the prior-year period, while Adjusted EBITDA increased to $16.1 million from $2.1 million.

Medical-cost performance improved year over year. Consolidated Gross profit increased 77.3% to $129.8 million, outpacing revenue growth, and the Insurance BER improved by (240 bps) to 91.1%. The nine-month Insurance BER was 88.4%, compared with 89.4% in the prior-year period. These results accompanied 56.7% nine-month revenue growth to $2,251.7 million and nine-month GAAP net income of $61.8 million, compared with a $(36.2) million loss.

Expense trends show both operating leverage and areas requiring attention. GAAP SG&A increased 26.5% to $122.8 million in the quarter, materially slower than revenue growth. However, Adjusted SG&A increased 60.1% to $113.8 million, and Adjusted SG&A as a percentage of Total revenues increased to 15.0% from 14.3%. Other income declined to $10,520 thousand from $17,522 thousand. Unpaid claims rose to $269,101 thousand at September 30, 2026, from $153,250 thousand at December 31, 2025.

Liquidity increased during the nine-month period. Total cash, cash equivalents, and investments were $512.6 million, compared with $395.9 million at September 30, 2025. Net cash provided by operating activities was $203,462 thousand, compared with $1,218 thousand in the prior-year period. Cash and cash equivalents ended the period at $268,067 thousand, up from $78,301 thousand at December 31, 2025.

The company raised the low end of all disclosed full-year 2026 guidance ranges. Revenue guidance is now $2.97 billion - $3.00 billion, GAAP Net income guidance is $25 million - $35 million, Consolidated Gross profit guidance is $540 million - $555 million, Adjusted EBITDA guidance is $75 million - $85 million, and average Medicare Advantage membership guidance is 157,000 - 158,000. Management also highlighted 2027 AEP tracking, maturing member cohorts, operating leverage, and the 5 Star rating for its flagship PPO for Payment Year 2028.

Management, verbatim

Our results further demonstrate our technology-powered differentiation, and how earlier and better care management, market-leading growth, and increasing profitability can reinforce one another under the right model.

Andrew Toy, Clover Health CEO

Through Clover Assistant, we are committed to delivering better clinical quality and lower total cost of care. We are pleased that this continues to show up in our results, with ~98% of our members enrolled in our 5 Star rated PPO for Payment Year 2028, alongside our third consecutive year of nation-leading HEDIS performance.

Andrew Toy, Clover Health CEO

In 2026, Clover is on track to have grown significantly and expects to deliver its first full year of GAAP Net Income profitability.

Clay Thornton, Clover Health CFO

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported quarterly metrics were not provided.
  • Free cash flow was not reported.
  • Debt was not reported.
  • Dividends were not reported.
  • Non-GAAP earnings per share were not reported.
  • Gross margin was not reported.
  • Operating margin was not reported.
  • Forward guidance for gross margin, operating expenses, and tax rate was not provided.
  • The previous outlook covered the full year 2026 only, and this quarterly release cannot be compared with full-year guidance.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second quarter 2026

AlphAI · Earnings readCLOV · Second quarter 2026 · ended June 30, 2026

Clover Health Reports Second Quarter 2026 Results

✓Strong quarter

Second-quarter revenue, membership, Consolidated Gross profit, Adjusted EBITDA, and GAAP net income all increased year-over-year, while the company increased full-year 2026 guidance across reported metrics.

Revenue
$743M
55.6% y/y
Insurance Segment
$738M
57.0% y/y
Full Year 2026 outlook
$2.92 billion - $3.00 billion
GM $525 million - $555 million

Actuals vs. the company’s prior outlook

from its previous release
MetricGuidedReportedVerdict
Total revenues$2.81 billion - $2.92 billionSecond quarter 2026: $743.2 millionn/a
Consolidated Gross profit$470 million - $510 millionSecond quarter 2026: $153.0 millionn/a
Adjusted EBITDA$50 million - $70 millionSecond quarter 2026: $40.9 millionn/a
GAAP Net income$0 million - $20 millionSecond quarter 2026: $28.0 millionn/a
Average Medicare Advantage membership154,000 - 158,000Second quarter 2026: 156,840n/a

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenuesGAAP$743.2M–55.6%
Consolidated Gross profitnon-GAAP$153M–53.6%
Salaries and benefits plus General and administrative expenses (SG&A)GAAP$124.4M–13.3%
Adjusted Salaries and benefits plus General and administrative expenses (Adjusted SG&A)non-GAAP$112.1M–35.9%
Adjusted SG&A as a % of Total revenuesnon-GAAP15.1%–(220 bps)
Net incomeGAAP$28M–N/A*
Adjusted EBITDAnon-GAAP$40.9M–139.2%
Adjusted Net incomenon-GAAP$40.4M–141.9%
Average Medicare Advantage membershipother156,840–48.7%
Insurance net medical claims incurredGAAP$615.4M–56.1%
Insurance BERnon-GAAP87.6%–(80 bps)
Total revenues, six months ended June 30GAAP$1.49B–58.8%
Consolidated Gross profit, six months ended June 30non-GAAP$312.5M–49.9%
Salaries and benefits plus General and administrative expenses (SG&A), six months ended June 30GAAP$256.1M–16.7%
Adjusted Salaries and benefits plus General and administrative expenses (Adjusted SG&A), six months ended June 30non-GAAP$231.4M–39.7%
Adjusted SG&A as a % of Total revenues, six months ended June 30non-GAAP15.5%–(210 bps)
Net income, six months ended June 30GAAP$55.3M–N/A*
Adjusted EBITDA, six months ended June 30non-GAAP$81.2M–89.3%
Adjusted Net income, six months ended June 30non-GAAP$80.1M–90.7%
Average Medicare Advantage membership, six months ended June 30other155,723–50.1%
Insurance net medical claims incurred, six months ended June 30GAAP$1.23B–60.8%
Insurance BER, six months ended June 30non-GAAP87.1%–(20 bps)
Insurance membersother157,309––

Segments

SegmentRevenueq/qy/y
Insurance SegmentAverage Medicare Advantage membership was 156,840, up 48.7% year-over-year.$737.8M–57.0%
Insurance Segment, six months ended June 30Average Medicare Advantage membership was 155,723, up 50.1% year-over-year.$1.48B–59.9%

Full Year 2026 outlook

  • Revenue$2.92 billion - $3.00 billion
  • Gross margin$525 million - $555 million
  • NoteAdjusted EBITDA profitability between $70 million and $85 million
  • NoteGAAP Net income between $20 million and $35 million
  • NoteAverage Medicare Advantage membership of 156,000 - 158,000

What drove it

  • Second-quarter average Medicare Advantage membership was 156,840, up 48.7% year-over-year.
  • Insurance revenue was $737.8 million, up 57.0% year-over-year.
  • Insurance BER was 87.6%, compared with 88.4%, a change of (80 bps).
  • Adjusted SG&A as a percentage of Total revenues was 15.1%, compared with 17.3%, a change of (220 bps).
  • Management cited strong cohort development, continued clinical engagement, and the added flexibility of a 4.5 Star payment year in discussing confidence for 2027.

Concerns

  • Insurance net medical claims incurred increased 56.1% year-over-year to $615.4 million.
  • The company operates at full risk, according to Interim CFO Clay Thornton.
  • Full-year projected Consolidated Gross profit and Adjusted EBITDA reconciliations to GAAP measures were not provided because certain items were described as inherently uncertain and difficult to predict or not reasonably calculable without unreasonable efforts.

What to watch

  • Execution against full-year 2026 Total revenues guidance of $2.92 billion - $3.00 billion.
  • Execution against full-year 2026 Consolidated Gross profit guidance of $525 million - $555 million.
  • Execution against full-year 2026 Adjusted EBITDA profitability guidance of $70 million - $85 million.
  • Execution against full-year 2026 GAAP Net income guidance of $20 million - $35 million.
  • Average Medicare Advantage membership relative to full-year guidance of 156,000 - 158,000.
  • Insurance BER and cohort economics as members mature under the technology-powered care model.

Balance sheet and cash flow

  • Total cash, cash equivalents, and investments: $443.0 million, compared with $389.3 million, up 13.8%.
  • Operating cash flow was not reported in the provided filing text.
  • Free cash flow was not reported in the provided filing text.

Analysis

Clover Health reported a strong second quarter, led by Medicare Advantage enrollment growth and revenue expansion. Total revenues were $743.2 million, up 55.6% year-over-year, while Insurance revenue was $737.8 million, up 57.0%. Average Medicare Advantage membership increased 48.7% to 156,840, and Insurance members as of June 30, 2026 were 157,309 compared with 106,323 as of June 30, 2025.

Profitability improved materially. GAAP net income was $28.0 million compared with a net loss of $(10.6) million, while Adjusted EBITDA increased 139.2% to $40.9 million and Adjusted Net income increased 141.9% to $40.4 million. Consolidated Gross profit, a non-GAAP measure, rose 53.6% to $153.0 million.

Expense leverage was evident in the reported SG&A metrics. GAAP SG&A rose 13.3% to $124.4 million, materially below the 55.6% increase in Total revenues. Adjusted SG&A as a percentage of Total revenues declined to 15.1% from 17.3%, a change of (220 bps). Insurance net medical claims incurred rose 56.1% to $615.4 million, while the non-GAAP Insurance BER improved to 87.6% from 88.4%.

The first-half figures also show continued expansion, with Total revenues of $1,492.4 million, Consolidated Gross profit of $312.5 million, GAAP net income of $55.3 million, and Adjusted EBITDA of $81.2 million. First-half average Medicare Advantage membership was 155,723, and first-half Insurance BER was 87.1%, compared with 87.3% in the prior-year period.

Management raised full-year 2026 guidance across the reported measures. The company now expects Total revenues of $2.92 billion - $3.00 billion, Consolidated Gross profit of $525 million - $555 million, Adjusted EBITDA profitability of $70 million - $85 million, GAAP Net income of $20 million - $35 million, and average Medicare Advantage membership of 156,000 - 158,000. The filing identifies strong cohort development, continued clinical engagement, and a 4.5 Star payment year as support for increased confidence in the 2027 outlook.

Management, verbatim

Our results demonstrate that a wide-network, full-risk Medicare Advantage model can deliver better health outcomes, meaningful growth, and increasing profitability at the same time,

Andrew Toy, CEO

We are continuing to bring our AI-powered Clover Assistant platform to more physicians and more members, empowering earlier intervention, more personalized care, and better health outcomes. We believe this differentiated approach is the foundation for our long-term earnings potential.

Andrew Toy, CEO

The underlying performance of our Medicare Advantage business continued to strengthen through the first half of the year, with cohort economics improving year-over-year as expected, giving us the confidence to raise our full-year 2026 outlook,

Clay Thornton, Interim CFO

Not in the filing

stated, not guessed
  • GAAP gross margin was not reported.
  • GAAP operating income was not reported.
  • GAAP and non-GAAP earnings per share were not reported.
  • Quarter-over-quarter comparisons were not reported for the listed metrics.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Debt was not reported.
  • Share repurchases, dividends, and other capital returns were not reported.
  • Guidance for operating expenses was not reported.
  • Guidance for tax rate was not reported.
  • Full-year 2026 actual results are not reported; therefore, the prior full-year guidance ranges cannot be assessed against a same-period full-year actual.
  • Revenue for segments other than the Insurance Segment was not reported in the provided filing text.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CLOV earnings dates

When is Clover Health Investments's next earnings date?
AlphAI has no date for CLOV yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.